Author

A. Schlosser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cell signaling & trafficking· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Organism:C. elegans· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. E. Mayer· 1 shared A. Garcia-Garijo· 1 shared A. Gros· 1 shared A. Loza Valdes· 1 shared A. Vidal· 1 shared A. Yuste-Estevanez· 1 shared C. Kisker· 1 shared E. Garralda· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. E. Mayer

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Peptide-stimulation of autologous T cells reverts immune checkpoint inhibitor resistance of hypermutated colorectal cancer cells

S. Schwarz, S. Zhaoran, M. Krohn, M. Loeffler, A. Schlosser, M. Linnebacher

The paper shows that pre-stimulating T cells with tumor-specific peptides can overcome immune checkpoint inhibitor resistance in hypermutated colorectal cancer cells.

bioRxiv · Feb 6, 2024 · PreprintCancer Biology

Immunogenicity of non-canonical HLA-tumor ligands identified through proteogenomics

M. Lozano-Rabella, A. Garcia-Garijo, J. Palomero, A. Yuste-Estevanez, F. Erhard, J. Martin-Liberal, M. Ochoa de Olza, I. Matos, J. J. Gartner, M. Ghosh, F. Canals, A. Vidal, J. M. Piulats, X. Matias-Guiu, I. Brana, , A. Gros

The paper investigates the immunogenicity of non-canonical HLA-I ligands from tumor cells and finds they are not recognized by autologous T-cells but can be targeted by donor T-cells, suggesting potential as immunotherapy targets.

Clinical Cancer Research · Feb 7, 2023Peer-reviewedCancer Biology

Structural basis for the activation of CDK7 by MAT1 and Cyclin H

S. Peissert, A. Schlosser, R. Kendel, J. Kuper, C. Kisker

The paper solves the structure of the CAK complex from C. thermophilum and shows MAT1-dependent CDK7 activation independent of T-loop phosphorylation.

bioRxiv · Aug 20, 2020Biochemistry

A phosphoproteomic approach reveals that PKD3 controls phenylalanine and tyrosine metabolism

A. E. Mayer, A. Loza Valdes, W. Schmitz, J. Trujillo Viera, M. Leitges, A. Schlosser, G. Sumara

This study identifies PKD3 as a regulator of phenylalanine to tyrosine conversion in the liver through phosphoproteomic analysis.

bioRxiv · Jul 20, 2020Biochemistry